title: Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
abstract: Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.
authors.affiliation: Division of Hematology/Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, Mount Sinai School of Medicine, 1 Gustave L Levy Pl, New York, NY 10029, USA.
authors.forename: Tracy
authors.initials: T
authors.lastname: Proverbs-Singh
authors.forename: Sophia K
authors.initials: SK
authors.lastname: Chiu
authors.forename: Ziyue
authors.initials: Z
authors.lastname: Liu
authors.forename: Sonia
authors.initials: S
authors.lastname: Seng
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: Che-Kai
authors.initials: CK
authors.lastname: Tsao
authors.forename: Menggang
authors.initials: M
authors.lastname: Yu
authors.forename: Noah M
authors.initials: NM
authors.lastname: Hahn
authors.forename: William K
authors.initials: WK
authors.lastname: Oh
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001158:Arteries; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin